BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2077 related articles for article (PubMed ID: 25777974)

  • 21. Prognostic value of pretreatment carcinoembryonic antigen after definitive radiotherapy with or without concurrent chemotherapy for squamous cell carcinoma of the uterine cervix.
    Huang EY; Hsu HC; Sun LM; Chanchien CC; Lin H; Chen HC; Tseng CW; Ou YC; Chang HY; Fang FM; Huang YJ; Wang CY; Lu HM; Tsai CC; Ma YY; Fu HC; Wang YM; Wang CJ
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1105-13. PubMed ID: 20932670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Outcomes and prognostic factors of distant metastasis in patients with advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy].
    Ma R; Zhang H; Zou L; Qu Y
    Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):125-30. PubMed ID: 25877610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Treatment Time on Chemoradiotherapy in Locally Advanced Cervical Carcinoma.
    Pathy S; Kumar L; Pandey RM; Upadhyay A; Roy S; Dadhwal V; Madan R; Chander S
    Asian Pac J Cancer Prev; 2015; 16(12):5075-9. PubMed ID: 26163644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of semiextended field intensity-modulated radiation therapy and concurrent cisplatin in locally advanced cervical cancer patients: An observational study of 10-year experience.
    Lee J; Lin JB; Sun FJ; Chen YJ; Chang CL; Jan YT; Wu MH
    Medicine (Baltimore); 2017 Mar; 96(10):e6158. PubMed ID: 28272204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
    Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
    J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Chemotherapy intensity importance in concurrent chemoradiotherapy of locally advanced cervical cancer].
    Sirák I; Petera J; Odrázka K; Dolezel M; Zoul Z; Vaculíková M
    Ceska Gynekol; 2006 Jul; 71(4):308-11. PubMed ID: 16956043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
    Lim A; Sia S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1431-8. PubMed ID: 21640504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Utility of Pretreatment and Posttreatment Lymphopenia in Cervical Squamous Cell Carcinoma Patients Treated With Definitive Chemoradiotherapy.
    Onal C; Yildirim BA; Guler OC; Mertsoylu H
    Int J Gynecol Cancer; 2018 Oct; 28(8):1553-1559. PubMed ID: 30247248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patterns of failure after use of (18)F-FDG PET/CT in integration of extended-field chemo-IMRT and 3D-brachytherapy plannings for advanced cervical cancers with extensive lymph node metastases.
    Chung YL; Horng CF; Lee PI; Chen FL
    BMC Cancer; 2016 Mar; 16():179. PubMed ID: 26940959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk stratification for failure in patients with advanced cervical cancer after concurrent chemoradiotherapy: another way to optimise treatment results.
    Liang JA; Chen SW; Chang WC; Hung YC; Yeh LS; Yang SN; Lin FJ
    Clin Oncol (R Coll Radiol); 2008 Nov; 20(9):683-90. PubMed ID: 18676129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of radiation dose and standardized uptake value of (18)FDG PET on nodal control in locally advanced cervical cancer.
    Ramlov A; Kroon PS; Jürgenliemk-Schulz IM; De Leeuw AA; Gormsen LC; Fokdal LU; Tanderup K; Lindegaard JC
    Acta Oncol; 2015; 54(9):1567-73. PubMed ID: 26271799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study.
    Zhang GY; Zhang R; Bai P; Li SM; Zhang YY; Chen YR; Huang MN; Wu LY
    BMC Cancer; 2022 Dec; 22(1):1331. PubMed ID: 36539745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended-field intensity-modulated radiotherapy and concurrent cisplatin-based chemotherapy for postoperative cervical cancer with common iliac or para-aortic lymph node metastases: a retrospective review in a single institution.
    Zhang G; Fu C; Zhang Y; Wang J; Qiao N; Yang Q; Cheng Y
    Int J Gynecol Cancer; 2012 Sep; 22(7):1220-5. PubMed ID: 22854654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group.
    Marnitz S; Martus P; Köhler C; Stromberger C; Asse E; Mallmann P; Schmidberger H; Affonso Júnior RJ; Nunes JS; Sehouli J; Budach V
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):243-53. PubMed ID: 26853333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule.
    Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
    Gynecol Oncol; 2012 Aug; 126(2):211-6. PubMed ID: 22555110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Definite chemoradiotherapy is a competent treatment option in FIGO stage IB2 cervical cancer compared with radical surgery +/- neoadjuvant chemotherapy.
    Hsieh HY; Huang JW; Lu CH; Lin JC; Wang L
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):99-108. PubMed ID: 29429800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The predictive value of serum squamous cell carcinoma antigen in patients with cervical cancer who receive neoadjuvant chemotherapy followed by radical surgery: a single-institute study.
    Li X; Zhou J; Huang K; Tang F; Zhou H; Wang S; Jia Y; Sun H; Ma D; Li S
    PLoS One; 2015; 10(4):e0122361. PubMed ID: 25860888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment outcomes of locally advanced cervical cancer by histopathological types in a single institution: A propensity score matching study.
    Yin KC; Lu CH; Lin JC; Hsu CY; Wang L
    J Formos Med Assoc; 2018 Oct; 117(10):922-931. PubMed ID: 30025761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study.
    Gandhi AK; Sharma DN; Rath GK; Julka PK; Subramani V; Sharma S; Manigandan D; Laviraj MA; Kumar S; Thulkar S
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):542-8. PubMed ID: 24074927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparative analysis of neoadjuvant therapies in stage Ib2 and IIa2 cervical carcinoma].
    Hu JL; Wu LY; Li N; Li XG; Huang MN; Zhang R
    Zhonghua Fu Chan Ke Za Zhi; 2012 Jun; 47(6):452-7. PubMed ID: 22932113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 104.